NCT07521046

Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)

A Phase 1b Study of Safety, Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: University of Utah · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.

Conditions

• Myelofibrosis

Interventions

Type	Name	Description
DRUG	ropeginterferon alfa- 2b	Ropeginterferon alfa- 2b will be administered as a subcutaneous injection every two weeks.
DRUG	Ruxolitinib	Ruxolitinib will be administered per standard of care.

Timeline

• Start date: 2026-05-01
• Primary completion: 2029-05-01
• Completion: 2030-05-01
• First posted: 2026-04-09
• Last updated: 2026-04-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study